AbbVie moves to dismiss US antitrust case over Humira
MLex Summary: AbbVie told a US federal court that responding to biosimilar competition to its branded drug Humira by launching innovative new drugs, reducing prices for health plans, and increasing choices...To view the full article, register now.
Already a subscriber? Click here to view full article